智通财经APP获悉，诺和诺德(NVO.US)的减肥药Wegovy曾为其带来巨大收益，但最近的销售势头似乎正在减弱。摩根大通分析师预测其第三季度Wegovy的销售将低于预期，导致诺和诺德在欧洲股价下跌至七个月最低点，较6月历史高点下跌约20%，市值蒸发 ...

丹麦制药公司诺和诺德的股价在周五遭受打击，此前摩根大通的分析师预计该公司即将发布的第三季度业绩可能低于预期，特别是其畅销减肥药Wegovy的销售情况。这一预测使得诺和诺德的股价一度下跌4.6%，延续了近期的下跌趋势。尽管如此，摩根大通的理查德·沃瑟 ...

智通财经APP获悉，诺和诺德(NVO.US)的减肥药Wegovy曾为其带来巨大收益，但最近的销售势头似乎正在减弱。摩根大通分析师预测其第三季度Wegovy的销售 ...

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

智通财经APP注意到，Ozempic 和 Wegovy 为 诺和诺德 (NVO.US)公司赚取了巨额利润，它们的累计销售额很快就会超过这家制药商过去 30 年的全部研发预算。而 ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

约根森则辩称，自2017年首次投放市场以来，Ozempic的净价已经下降了约40%，Wegovy自2021年以来也出现了类似的下降。净价是指制药公司扣除回扣和折扣后从药品中赚取的利润。

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers ...